معرفی
Trond Ulven is a Professor of Medicinal Chemistry at the Department of Drug Design and Pharmacology, University of Copenhagen since January 2018. Previously, he served as Professor at the University of Southern Denmark from 2012-2018, holding positions with special responsibilities in entrepreneurship. He is also the Director and co-founder of Caldan Therapeutics since 2015, demonstrating his commitment to translational research.
His educational background includes:
- Doctor engineer (dr.ing.) of Organic Chemistry, Norwegian University of Science and Technology (NTNU), 1999
- Civil engineer (siv.ing.) of Organic Chemistry, Norwegian Institute of Technology (NTH), 1994
- Examen philosophicum, University of Trondheim, Norway, 1992
Professor Ulven's research focuses on medicinal chemistry and drug discovery, particularly targeting G protein-coupled 7-transmembrane receptors (GPCRs). His work emphasizes free fatty acid receptors, which show significant potential as drug targets for metabolic diseases. His research also extends to chemokine receptors and AMPK signaling within inflammation and metabolic disease contexts. His group develops synthetic methods to support structure-activity relationship studies and efficient compound identification, with continuous efforts to create simpler, more efficient, and greener synthetic approaches.
His extensive publication record (162 research outputs) demonstrates consistent productivity and relevance in the field. The research trends show a deep focus on GPCR pharmacology, particularly free fatty acid receptors (FFAR1, FFAR2, FFAR4) and GPR84. His work spans molecular pharmacology, medicinal chemistry optimization, and translational studies examining metabolic effects in animal models, integrating biochemical, cellular, and in vivo approaches to understand receptor function and develop therapeutic compounds.
Professor Ulven maintains an active research laboratory with significant industry connections through Caldan Therapeutics. His work has garnered attention across multiple platforms including X (formerly Twitter), Facebook, Bluesky, and news outlets, indicating impact within both scientific and broader communities. His research has practical applications in metabolic disease therapeutics, with publications appearing in high-impact journals including Nature, Nature Communications, Science Advances, and Journal of Medicinal Chemistry.
